SEARCH

SEARCH BY CITATION

References

  • 1
    El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:25572576.
  • 2
    Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999;29:6267.
  • 3
    Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693699.
  • 4
    Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2010;53:135.
  • 5
    Marrero JA, El-Serag HB. Alpha-fetoprotein should be included in the hepatocellular carcinoma surveillance guidelines of the American Association for the Study of Liver Diseases. Hepatology 2011;53:10601061; author reply 1061–1062.
  • 6
    Singal AG, Conjeevaram HS, Volk ML, Fu S, Fontana RJ, Askari F, et al. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev 2012;21:793799.
  • 7
    Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009;30:3747.
  • 8
    Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2010;138:493502.
  • 9
    Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009;137:110118.
  • 10
    Colli A, Fraquelli M, Casazza G, Massironi S, Colucci A, Conte D, et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol 2006;101:513523.
    Direct Link:
  • 11
    Lederle FA, Pocha C. Screening for liver cancer: the rush to judgment. Ann Intern Med 2012;156:387389.
  • 12
    Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130:417422.
  • 13
    Poustchi H, Farrell GC, Strasser SI, Lee AU, McCaughan GW, George J. Feasibility of conducting a randomized control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed?Hepatology 2011;54:19982004.
  • 14
    Jepsen P, Ott P, Andersen PK, Sorensen HT, Vilstrup H. Risk for hepatocellular carcinoma in patients with alcoholic cirrhosis: a Danish nationwide cohort study. Ann Intern Med 2012;156:841847.
  • 15
    Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127( suppl 1):S35S50.
  • 16
    Singal AG, Waljee A, Mukherjee A, Higgins P, Zhu J, Marrero JA. Machine learning algorithms outperform conventional regression models in identifying risk factors for hepatocellular carcinoma in patients with cirrhosis. Gastroenterology 2012;142( suppl 1):S984.
  • 17
    Davila JA, Henderson L, Kramer JR, Kanwal F, Richardson PA, Duan Z, et al. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med 2011;154:8593.
  • 18
    Singal AG, Volk ML, Rakoski MO, Fu S, Su GL, McCurdy H, et al. Patient involvement in healthcare is associated with higher rates of surveillance for hepatocellular carcinoma. J Clin Gastroenterol 2011;45:727732.
  • 19
    Singal AG, Yopp A, S Skinner C, Packer M, Lee WM, Tiro JA. Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review. J Gen Intern Med 2012:861867.
  • 20
    Stravitz RT, Heuman DM, Chand N, Sterling RK, Shiffman ML, Luketic VA, et al. Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med 2008;121:119126.
  • 21
    Singal AG, Yopp A, Gupta S, Skinner CS, Halm EA, Okolo E, et al. Failure rates in the hepatocellular carcinoma surveillance process. Cancer Prev Res (Phila) 2012;5:11241130.
  • 22
    Singal AG, Nehra M, Huet B, Marrero J, Lok AS, Lee WM. Failure rates in a surveillance program for hepatocellular carcinoma among patients in the HALT-C Trial. Gastroenterology 2012;142( suppl 1):S1008.